Listen to this article · 9 min listen

Investors and biz dev teams use the AI Health 100 to get their bearings in healthcare AI, but a company’s rank is just the headline. The real story, the part you can actually act on, is buried in the records that back up any claim about outcomes. A documented clinical decision support record that shows exactly how a reading was made and what outcome got attached is what turns a flimsy ‘segment claim’ into a solid ‘segment record’.

Looking at companies like HeartFlow, Hinge Health, and Tempus AI, you can see how the signals of solid clinical decision support, real revenue growth, and public company status come together. They all operate in different markets, but their growth stories are all built on the provable impact of their AI, especially with CDS. It’s simple: a real clinical decision support record documents the reading pathway and connects an outcome to it, which is the foundation for a credible listing. That’s the difference between a claim and a record.

The Foundational Role of Clinical Decision Support Records

Any AI health company worth its salt has to show a clear, documented pathway for its clinical decision support (CDS). This means having a real evidence base, something that can stand up to peer review, showing the AI actually improves workflow. Clinicians and physicians are the key audience here, and they’re digging into the evidence for any new CDS tool, wanting proof that it will genuinely help patients and make their jobs easier, not just generate more alerts PubMed clinical decision support evidence.

Take HeartFlow in the cardiac diagnostics space, where you can’t afford to be wrong. Their FFRct technology for non-invasive coronary assessment is a perfect example of AI guiding tough clinical calls, and the market clearly agreed. The company went public on NASDAQ in August 2025, raising about $364.2 million, which is a massive vote of confidence built on strong clinical groundings. As the first AI cardiac diagnostic company to IPO, HeartFlow literally created the public market for cardiac AI, giving everyone else a benchmark. That IPO, which came after they’d already raised over $936 million in total funding, shows that the sector is growing up. Solid clinical evidence is what brings investor money to the table.

Investors also need to know the difference between Clinical Decision Support and Diagnostic AI. CDS just gives recommendations and might fly under the regulatory radar, but Diagnostic AI makes its own calls and is regulated as a medical device (a huge difference). A company that’s upfront about its AI’s function and its specific regulatory path is building trust and giving you a much cleaner investment case. Without that well-documented clinical decision support record, the one showing the reading pathway and the attached outcome, an outcomes claim just falls apart.

Revenue Growth as a Signal of Market Adoption

Clinical proof is great, but revenue growth is how you know a product is actually getting adopted and can scale. It’s a hard number. The AI Health 100 rightly uses revenue growth, plus deployment expansion and the depth of enterprise contracts, as a key metric. You can see this play out with companies like Hinge Health and Tempus AI, which, like HeartFlow, are on revenue growth paths that prove they’re making a real dent in the market.

Hinge Health, a big name in the digital musculoskeletal (MSK) space, put up huge numbers, hitting $587.9 million in FY2025 revenue, a 51% jump year-over-year. They’re even forecasting revenue between $856 million and $860 million for 2026. This kind of growth shows just how big digital chronic care solutions can get Fierce Healthcare Hinge Health IPO details. Their IPO in May 2025, which raised $437 million at a valuation around $2.6 to $3 billion, really opened eyes in the digital health world and showed that the market is hungry for companies that can post big revenue at scale. Sure, they posted a GAAP operating loss of $546.4 million in 2025, but a 51% growth rate tells you this is a land-grab market that’s expanding fast.

Then you have Tempus AI in precision medicine, also posting massive revenue: $1.27 billion for 2025, with a trailing 12-month revenue of $1.36 billion as of 2026. These aren’t just vanity metrics. For any private healthcare AI company, these public numbers set the bar for what’s possible and show what the revenue ceiling for digital health looks like right now. With growth rates for these public companies sitting between 49% and 55%, it’s clear they’re still in a high-growth phase and nowhere near topping out their market cycles.

When a company can pull in that much revenue, especially with those growth rates, it tells investors everything they need to know: the solution works in the clinic, it works on the balance sheet, and it’s getting baked into how healthcare gets delivered.

The Public Company Dimension and Market Maturation

Going public is a huge step for any AI health company, forcing a new level of maturity, transparency, and accountability. The IPOs for HeartFlow on NASDAQ in August 2025 and Hinge Health on the NYSE in May 2025 aren’t isolated events. They show that digital health is moving out of the venture-funded sandbox and into the public arena. This creates a real, public market for AI health solutions, giving everyone direct comparisons and setting clear benchmarks for valuation and growth.

Once a company enters the public market, it’s also playing with a new set of rules, from SEC IPO requirements to Sarbanes-Oxley compliance. All that extra scrutiny is good, as it forces validation of their clinical and revenue claims since public companies have to make rigorous financial and operational disclosures. For an investor, a public company means more liquidity and a much clearer way to think about valuation, letting you make apples-to-apples comparisons in the sector.

These three companies, HeartFlow, Hinge Health, and Tempus AI, are the case studies for this market maturation. HeartFlow’s IPO created a public market for cardiac AI diagnostics. Hinge Health’s IPO set the bar for digital chronic care with its huge valuation and revenue. And Tempus AI, which hit NASDAQ in June 2024, is already part of the same revenue benchmark conversations, showing its scale and market heft.

What Investors and Business Development Teams Can Independently Verify

So if you’re an investor or on a biz dev team looking at a company on the AI Health 100, its credibility comes down to what you can verify with your own eyes. It all goes back to the clinical decision support record giving shape to an outcomes claim: you need to see the documented reading pathway and the outcome attached to it. That’s what makes a company’s story a ‘segment record’ instead of just a ‘segment claim’.

You can check for several key signals on your own, without even talking to a vendor:

  • Clinical Decision Support Documentation: Go find the peer-reviewed publications and clinical studies that actually document the AI’s reading pathway and the outcomes. You’re looking for sources like AHA Journals and PubMed AHA Journals AI in Cardiology. A company like Hello Heart, for example, has its credibility backed up by more than six peer-reviewed studies and a partnership with the American College of Cardiology. That’s real evidence.
  • Revenue Growth Data: For public companies, just go to their SEC filings. That’s where you’ll find verifiable revenue numbers and growth rates. Hinge Health’s FY2025 revenue of $587.9 million at 51% growth isn’t a guess. It’s right there in the public record.
  • Public Company Status: You can confirm IPOs and stock exchange listings through any financial news outlet or by checking SEC filings. Seeing HeartFlow on NASDAQ or Hinge Health on the NYSE is a dead-simple indicator of where they are in their lifecycle.

Some of the data you’ll find, like Hello Heart’s $56 million valuation back in July 2019 or its $139.3 million total funding over 6 rounds, will come from marketplace sources like Forge Global or Crunchbase. That’s fine, but you have to say where it came from and try to cross-reference it if you can Forge Global Hello Heart valuation. The bottom line is you have to focus on documented outcomes and real growth numbers, not vendor projections or claims they can’t back up with paper.

If you focus on these verifiable signals, you’ll see past a company’s rank on a list and get a real understanding of the fastest-growing AI health players and what they’re actually worth.

Frequently Asked Questions

What is the primary factor that elevates a company’s outcomes claim to a ‘segment record’ in the AI Health 100 ranking?

The primary factor is a meticulously documented clinical decision support record. This record outlines how a reading is made and an outcome is attached, providing an evidence base for the AI tool’s effectiveness and demonstrating its impact.

Why is a clear, documented pathway for clinical decision support important for AI health companies?

It is crucial because it provides an evidence base for AI tools that improve workflow and withstand peer review. Clinicians and physicians scrutinize this evidence to ensure the tools genuinely enhance patient care and operational efficiency, building trust and a clearer investment thesis.

How do Clinical Decision Support (CDS) and Diagnostic AI differ, and why is this distinction important for investors?

CDS provides recommendations and may be unregulated, while Diagnostic AI makes independent determinations and is regulated as a medical device. This distinction is important for investors as companies that clearly delineate their AI’s function and regulatory pathway build trust and offer a clearer investment thesis.

What role does revenue growth play in the AI Health 100 ranking and for investors?

Revenue growth serves as a tangible indicator of market adoption and scalability, being a key criterion in the ranking. For investors, significant revenue, especially with strong growth percentages, signals that AI health solutions are not only clinically effective but also commercially viable and integrated into healthcare delivery.